Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome
Science Advances · 21.03.2025 · 11 (12)
DOI: 10.1126/sciadv.adi9885 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Science Advances, erschienen am 21.03.2025. Verfasst von Jessica C Hargarten und 18 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Immunology and Microbiology (LCIM), Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseas…. Hauptthemen laut MEDLINE: Meningoencephalitis, Neuroinflammatory Diseases, Pyrazoles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA.
Abstract (Originalsprache)
Therapies to reduce neuroinflammation following resolution of acute central nervous system (CNS) infections are urgently needed, particularly for patients with non–HIV-associated cryptococcal meningoencephalitis complicated by a postinfectious inflammatory response syndrome (cPIIRS). To identify druggable targets in cPIIRS, patient cerebral spinal fluid samples underwent transcriptional analysis, revealing a Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway dominance in neuroinflammatory gene signatures. MurinecPIIRS models recapitulated this pathway predominance and treatment with the JAK inhibitor ruxolitinib, confirmed a mechanistic requirement for this pathway in disease pathology. Ruxolitinib treatment improved markers of neuronal damage, reduced activated T cell and myeloid cells, and improved weight. On the basis of these findings, we conducted a first-in-human ruxolitinib treatment of patients with cPIIRS (NCT00001352). Ruxolitinib treatment of six patients led to demonstrated tolerability, reductions in inflammatory biomarkers and activated immune cells, and improved brain imaging. These results advocate for pathway-instructed therapeutics in neuroinflammatory diseases and endorse JAK inhibitors in further clinical studies of cPIIRS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Immunology and Microbiology (LCIM), Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
- Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
- Research Service, Ann Arbor Veterans Affairs (VA) Healthcare System, Department of Veterans Affairs Health System, Ann Arbor, MI, USA.
- Integrated Data Science Section, NIAID, NIH, Bethesda, MD, USA.
- Genomic Research Section, Research Technologies Branch, NIAID, NIH, Bethesda, MD, USA.
ORCID-Profile: Jessica C Hargarten, Kenneth Ssebambulidde, Malcolm J Vaughan, Jintao Xu, Anutosh Ganguly, Brittany Dulek, Francisco Otaizo-Carrasquero, Yoon-Dong Park, Terri L Scott, Tracey-Ann Höltermann, Prashant Chittiboina, Bridgette Jeanne Billioux, Dima A Hammoud, Michal A Olszewski, Peter R Williamson
Förderung
- BLRD VA
Zitieren
APA
Hargarten, J. C., Ssebambulidde, K., Anjum, S. H., Vaughan, M. J., Xu, J., Ganguly, A., Dulek, B., Otaizo-Carrasquero, F., Song, B., Tao, S., Park, Y. D., Scott, T. L., Höltermann, T. A., Schinazi, R. F., Chittiboina, P., Billioux, B. J., Hammoud, D. A., Olszewski, M. A., & Williamson, P. R. (2025). Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome. Science Advances, 11(12). https://doi.org/10.1126/sciadv.adi9885
Vancouver
Hargarten JC, Ssebambulidde K, Anjum SH, Vaughan MJ, Xu J, Ganguly A, et al. Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome. Science Advances. 2025;11(12). doi:10.1126/sciadv.adi9885
BibTeX
@article{Hargarten2025,
author = {Hargarten, Jessica C and Ssebambulidde, Kenneth and Anjum, Seher H and Vaughan, Malcolm J and Xu, Jintao and Ganguly, Anutosh and Dulek, Brittany and Otaizo-Carrasquero, Francisco and Song, Brian and Tao, Sijia and Park, Yoon-Dong and Scott, Terri L and Höltermann, Tracey-Ann and Schinazi, Raymond F and Chittiboina, Prashant and Billioux, Bridgette Jeanne and Hammoud, Dima A and Olszewski, Michal A and Williamson, Peter R},
title = {Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {12},
doi = {10.1126/sciadv.adi9885}
}
EUVIMED